March 13th 2024
This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.
New Formulation of Cabotegravir for HIV Treatment Can be Dosed at Intervals of at Least 4 Months
March 4th 2024In a phase 1 study, the investigational therapy known as cabotegravir ultra long-acting (CAB-ULA), showed positive pharmacokinetic, tolerability, and safety data supporting a prospective move to the next stage of clinical development.
Read More
A Strategy for Reducing STIs Through Implementing Doxycycline Post-Exposure Prophylaxis
March 4th 2024Study presented at CROI 2024 reveals that the introduction of Doxycycline post-exposure prophylaxis (doxy-PEP) guidelines in San Francisco has significantly decreased the incidence of chlamydia and syphilis
Read More
Assessing and Improving the Health-Related Quality of Life Among People Who Inject Drugs
February 1st 2024People who inject drugs (PWID) are at a higher risk for hepatitis C and HIV. A new study examined point of care initiatives and how to better support this population with intervention efforts.
Read More
World AIDS Day Marks Success, Progress, and Challenges That Remain
December 1st 2023Therapy development, management improvements, and public health initiatives have all helped to change the trajectory of health outcomes for many, but still millions of people remain behind and are not in the continuum of care.
Read More
Massachusetts Hospital Faces Lawsuit Over Potential Hepatitis and HIV Exposure
November 30th 2023Salem Hospital faces a class action lawsuit over potential hepatitis and HIV exposure to hundreds of patients. The lawsuit alleges negligence and emotional distress, with the hospital claiming a minimal infection risk.
Read More
2 Year Data on Lenacapavir Reinforces Clinical Profile for Adults With Multi-Drug Resistant HIV
October 21st 2023The antiretroviral, lenacapavir (Sunlenca 463.5 mg/1.5 mL injection), had reported resistance in only a minority of study participants according to the latest findings released at a conference.
Read More
WHO Updates Recommendations for HIV, Hepatitis, STI Interventions in Prisons
July 26th 2023The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.
Read More
Prophylactic Statin Therapy Can Reduce Cardiovascular Events in People with HIV
July 24th 2023A new study shows the use of statin therapy in a primary prevention cohort of patients with HIV on antiretroviral therapy was associated with a 35% reduction in risk of cardiovascular events. The data is being reported at the International AIDS Society Conference.
Read More
Almost Zero Risk of Sexually Transmitting HIV From People on ART with Low Levels of Virus
July 23rd 2023New study demonstrates benefit of adhering to treatment regimen and also calls for simplifying viral testing in other parts of the world where updated panels technology may not be available.
Read More